Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has reported net sales of $12.58bn for the third quarter ended 30 September 2010, an increase of 13%, compared to $11.09bn for the same period in 2009.
Subscribe to our email newsletter
Novartis posted a net income of $2.31bn for the third quarter 2010, compared to $2.11bn for the comparable period in 2009.
The operating loss was $2.59bn, compared to $2.63bn for the comparable period in 2009.
Novartis said that the 2% loss in operating income is principally due to the termination of two development projects and Alcon related charges of $217m.
For the nine months ended 30 September 2010, Novartis posted net sales of $36.43bn, an increase of 16% compared to $31.34bn for the year ago period.
Operating income for nine months ended 30 September 2010 was $9.06bn, an increase of 23% compared to $7.35, for the year ago period.
Novartis has generated a net income of $7.70bn, an increase of 26%, compared to $6.13bn for the year ago period.
Novartis CEO Joseph Jimenez said that approvals such as Gilenya, a breakthrough first-line oral treatment for multiple sclerosis, and Tasigna, a new first-line treatment for chronic myeloid leukemia, have the potential to change patients’ lives. Data on new medicines such as MenB, a meningococcal vaccine candidate, gives them confidence that their pipeline will continue to deliver.